These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 20419162)

  • 1. Heparanase promotes engraftment and prevents graft versus host disease in stem cell transplantation.
    Bitan M; Weiss L; Zeira M; Zcharia E; Slavin S; Nagler A; Vlodavsky I
    PLoS One; 2010 Apr; 5(4):e10135. PubMed ID: 20419162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effects of immature dendritic cells genetically modified to express sTNFR I on graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) in allogeneic bone marrow transplantation mice].
    Wang SH; Li DP; Zhang YJ; Zhang P; Zeng LY; Pan XY; Xu KL; Huang YH
    Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):88-93. PubMed ID: 22730654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A radio-resistant perforin-expressing lymphoid population controls allogeneic T cell engraftment, activation, and onset of graft-versus-host disease in mice.
    Davis JE; Harvey M; Gherardin NA; Koldej R; Huntington N; Neeson P; Trapani JA; Ritchie DS
    Biol Blood Marrow Transplant; 2015 Feb; 21(2):242-9. PubMed ID: 25459639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multilineage engraftment with minimal graft-versus-host disease following in utero transplantation of S-59 psoralen/ultraviolet a light-treated, sensitized T cells and adult T cell-depleted bone marrow in fetal mice.
    Bhattacharyya S; Chawla A; Smith K; Zhou Y; Talib S; Wardwell B; Cowan MJ
    J Immunol; 2002 Dec; 169(11):6133-40. PubMed ID: 12444116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cobalt protoporphyrine IX-mediated heme oxygenase-I induction alters the inflammatory cytokine response, but not antigen presentation after experimental allogeneic bone marrow transplantation.
    Ewing P; Hildebrandt GC; Planke S; Andreesen R; Holler E; Gerbitz A
    Int J Mol Med; 2007 Sep; 20(3):301-8. PubMed ID: 17671733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects.
    Reddy P; Teshima T; Hildebrandt G; Williams DL; Liu C; Cooke KR; Ferrara JL
    Blood; 2003 Apr; 101(7):2877-85. PubMed ID: 12433681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donor gamma delta T lymphocytes promote allogeneic engraftment across the major histocompatibility barrier in mice.
    Drobyski WR; Majewski D
    Blood; 1997 Feb; 89(3):1100-9. PubMed ID: 9028343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetics of in vivo elimination of suicide gene-expressing T cells affects engraftment, graft-versus-host disease, and graft-versus-leukemia after allogeneic bone marrow transplantation.
    Rettig MP; Ritchey JK; Prior JL; Haug JS; Piwnica-Worms D; DiPersio JF
    J Immunol; 2004 Sep; 173(6):3620-30. PubMed ID: 15356106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heparanase prevents the development of type 1 diabetes in non-obese diabetic mice by regulating T-cell activation and cytokines production.
    Bitan M; Weiss L; Zeira M; Reich S; Pappo O; Vlodavsky I; Slavin S
    Diabetes Metab Res Rev; 2008; 24(5):413-21. PubMed ID: 18561210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of cytokine production and V beta T-cell receptor subsets in irradiated recipients receiving portal or peripheral venous reconstitution with allogeneic bone marrow cells, with or without additional anti-cytokine monoclonal antibodies.
    Gorczynski RM; Chen Z; Zeng H; Gorczynski L; Terzioglu E
    Immunology; 1998 Feb; 93(2):221-9. PubMed ID: 9616372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
    Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
    Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Administration of interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host disease.
    Alpdogan O; Schmaltz C; Muriglan SJ; Kappel BJ; Perales MA; Rotolo JA; Halm JA; Rich BE; van den Brink MR
    Blood; 2001 Oct; 98(7):2256-65. PubMed ID: 11568014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ex vivo treatment of murine splenocyte-supplemented bone marrow inocula with mafosfamide prior to allogeneic transplantation in an attempt to prevent lethal graft-versus-host disease without compromising engraftment.
    Kohn FR; Sladek NE
    Immunopharmacol Immunotoxicol; 1988; 10(3):387-98. PubMed ID: 3058776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive therapy by transfusing expanded donor murine natural killer T cells can suppress acute graft-versus-host disease in allogeneic bone marrow transplantation.
    Yang J; Gao L; Liu Y; Ren Y; Xie R; Fan H; Qian K
    Transfusion; 2010 Feb; 50(2):407-17. PubMed ID: 19788510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amotosalen-treated donor T cells have polyclonal antigen-specific long-term function without graft-versus-host disease after allogeneic bone marrow transplantation.
    Hossain MS; Roback JD; Lezhava L; Hillyer CD; Waller EK
    Biol Blood Marrow Transplant; 2005 Mar; 11(3):169-80. PubMed ID: 15744235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of deoxyspergualin on graft-versus-host disease and graft- versus-leukemia in mice.
    Weiss L; Reich S; Slavin S
    Bone Marrow Transplant; 1996 May; 17(5):789-92. PubMed ID: 8733699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New strategies in allogeneic stem cell transplantation: immunotherapy using irradiated allogeneic T cells.
    Waller EK; Boyer M
    Bone Marrow Transplant; 2000 May; 25 Suppl 2():S20-4. PubMed ID: 10933181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of graft-versus-host disease by intrabone marrow injection of donor T cells: involvement of bone marrow stromal cells.
    Miyake T; Inaba M; Fukui J; Ueda Y; Hosaka N; Kamiyama Y; Ikehara S
    Clin Exp Immunol; 2008 Apr; 152(1):153-62. PubMed ID: 18307515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease.
    Pan L; Delmonte J; Jalonen CK; Ferrara JL
    Blood; 1995 Dec; 86(12):4422-9. PubMed ID: 8541530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of graft-versus-host disease and bone marrow rejection: kinetics of induction of tolerance by UVB modulation of accessory cells and T cells in the bone marrow inoculum.
    Oluwole SF; Engelstad K; James T
    Blood; 1993 Mar; 81(6):1658-65. PubMed ID: 8453111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.